Repare Therapeutics Inc.
RPTX
$1.78
-$0.06-3.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -29.54% | 125.96% | |||
| Gross Profit | 30.77% | -125.96% | |||
| SG&A Expenses | -21.21% | -13.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.25% | -9.33% | |||
| Operating Income | 28.15% | 9.33% | |||
| Income Before Tax | 44.41% | -3.49% | |||
| Income Tax Expenses | -32.97% | -- | |||
| Earnings from Continuing Operations | 44.27% | -4.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.27% | -4.79% | |||
| EBIT | 28.15% | 9.33% | |||
| EBITDA | 28.84% | 11.88% | |||
| EPS Basic | 44.70% | -4.60% | |||
| Normalized Basic EPS | 29.45% | 8.54% | |||
| EPS Diluted | 45.06% | -5.28% | |||
| Normalized Diluted EPS | 29.45% | 8.54% | |||
| Average Basic Shares Outstanding | 0.78% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.78% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||